SGLT2 Inhibitors Are Underrated Geroprotectors — Here Is the Evidence
Hypothesis
SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) are underrated geroprotectors that extend lifespan via AMPK activation, senescence reduction, and telomere preservation — with existing FDA approval and established safety profiles.
Evidence
Mouse data: 13-14% lifespan extension in male mice (NIA Interventions Testing Program) — placing SGLT2i among only 12 validated lifespan-extending compounds.
Human telomere data: Rare reversal of age-related telomere shortening after just 6 months of treatment (Cell Reports Medicine, 2025).
Mortality data: 43% lower all-cause mortality vs non-users in real-world data from 25,000+ patients.
Senescence reduction: 40-50% reduction in senescent cells in aortic tissue after 7-14 days of treatment via AMPK-dependent mechanisms.
Mechanism
AMPK activation → mTORC1 inhibition → reduced cellular senescence + improved mitochondrial function + enhanced autophagy.
Why Underrated
SGLT2 inhibitors are framed as diabetes/heart failure drugs despite: (1) robust geroprotective preclinical data, (2) existing safety data from millions of prescriptions, (3) low translation barrier vs. novel compounds requiring de novo development.
The clinical opportunity: repurposing as longevity interventions at lower doses than currently prescribed for metabolic disease.
Key Citations
- NIA Interventions Testing Program (lifespan data)
- Cell Reports Medicine 2025 (telomere reversal)
- GetHealthSpan longevity research review (2025)
- PMC11812426 (mechanism studies)